Breast

Neoadjuvant

HER2+

ECOG-ACRIN-EA1181
Phase II Preoperative
THP & Postoperative
HP in Patients Who
Achieve a Pathologic
Complete Response

PI: Telli
ECOG-ACRIN

ER+/HER-

If Biomarker Eligible

BRS0093
Phase III
Pembrolizumab
vs Placebo +/-
Neoadjuvant
Chemo Tx &
Adjuvant
Endocrine Tx in
Breast Cancer

PI: Telli
Merck

BRS0124
Umbrella,
Randomized,
Controlled,
Pre-Operative Trial
Testing Integrative
Subtype-Targeted
Therapeutics in
Hormone
Receptor-Positive,
HER2-Negative
Breast Cancer

PI: Caswell-Jin
Stanford

KEY

Pending
Open for Enrollment
Observational Study
Optimal Path
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu